Rheumnow Podcast Dr. Cush

Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay

Featuring Drs. Jack Cush, Yuz Yusof, and Andrea Fava

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Giant Cell Arteritis and Polymyalgia Rheumatica UpdateDr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different MechanismsDr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Top 3 Messages About JAK Inhibitor SafetyDr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
DMARDs and Herpes Zoster Vaccination: To Stop or Not To StopDr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Select your GCA TherapyDr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
 

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
OP0046 Effect on SI joint structural lesions with ixekizumabPOS0058 Effect on SI joint structural lesions with bimekizumab
Does Telemonitoring in SpA Work?Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpADr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Treat to Target Outcomes in Early AxSpADr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Early Diagnosis of Axial SpondyloarthritisDr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.
Imaging in Axial SpondyloarthritisDr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.